(moexipril HCl / hydrochlorothiazide)
7.5 mg/12.5 mg
15 mg/12.5 mg
15 mg/25 mg
uniretic® (moexipril hydrochloride/hydrochlorothiazide) is a combination of an angiotensin-converting enzyme (ACE) inhibitor, moexipril hydrochloride, and a diuretic, hydrochlorothiazide. Moexipril hydrochloride is a fine white to off-white powder. It is soluble (about 10% weight-to-volume) in distilled water at room temperature.
uniretic® is indicated for treatment of patients with hypertension. This fixed combination is not indicated for the initial therapy of hypertension (DOSAGE AND ADMINISTRATION).
In using uniretic®, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that uniretic® does not have a similar risk (see WARNINGS, Neutropenia/Agranulocytosis). In addition, ACE inhibitors, for which adequate data are available, cause a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Angioedema).
Media Articles Related to Uniretic (Moexipril / Hydrochlorothiazide)
Prehypertension in late pregnancy linked to poorer fetal outcomes
Source: Hypertension News From Medical News Today [2016.02.02]
Women who develop prehypertension after 36 weeks' gestation may be at greater risk of having a stillbirth or an underweight infant, according to researchers from Sweden.
Easily stressed teens have increased hypertension risk later in life
Source: Hypertension News From Medical News Today [2016.02.02]
Being an easily stressed 18-year-old might predict high blood pressure later in life, according to a study following the health of 1.5 million Swedish men.
Actelion receives Health Canada approval for Uptravi (selexipag) for the long-term treatment of pulmonary arterial hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.01.26]
Actelion has announced that Health Canada has granted a Notice of Compliance (NOC) approving the orally active, selective IP prostacyclin receptor agonist Uptravi (selexipag),originally discovered...
The age-related change of angiotensin receptor promotes hypertension
Source: Hypertension News From Medical News Today [2016.01.20]
Heterodimerization of AT1R with P2Y6R along with age promotes angiotensin II-induced hypertension.
Formulation scientists to rescue patients with pulmonary arterial hypertension
Source: Huntingtons Disease News From Medical News Today [2016.01.15]
Overview of a type of high blood pressure of the arteries of the lungs and the heart and a new patient-friendly inhalation treatment.
Published Studies Related to Uniretic (Moexipril / Hydrochlorothiazide)
Comparison between moexipril and atenolol in obese postmenopausal women with hypertension. [1998.09.20]
The present study investigated the effect of the new ACE-inhibitor moexipril versus the beta 1-adrenergic blocker atenolol on metabolic parameters, adverse events (AEs) and sitting systolic (SSBP) and sitting diastolic blood pressure (SDBP) in obese postmenopausal women with hypertension (stage I and II)...
Antihypertensive treatment in postmenopausal women: results from a prospective, randomized, double-blind, controlled study comparing an ACE inhibitor (moexipril) with a diuretic (hydrochlorothiazide). [1998.05]
The present study was designed to compare the safety and efficacy of the new angiotensin-converting enzyme inhibitor moexipril with that of hydrochlorothiazide (HCTZ) in postmenopausal women with mild-to-moderate hypertension. After a 4-week single-blind placebo period, 97 postmenopausal hypertensive women (42-74 years of age) with a sitting diastolic blood pressure (SDBP) of 95-114 mm Hg were randomized to receive either once daily moexipril 15 mg or HCTZ 25 mg for a 12-week double-blind treatment period.
Antihypertensive effectiveness of a very low fixed-dose combination of moexipril and hydrochlorothiazide. [1998.03]
The antihypertensive and metabolic effects of a fixed combination of very low dose of moexipril (MO), an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide (HCTZ) were tested in a multicenter, placebo (PBO) controlled, double-blind, parallel study of men (M) and women (W) with mild to moderate essential hypertension.
Usefulness of moexipril and hydrochlorothiazide in moderately severe essential hypertension. [1997.04]
The purpose of this study was to assess the efficacy and tolerability of the angiotensin-converting enzyme inhibitor moexipril alone and in combination with hydrochlorothiazide versus hydrochlorothiazide monotherapy in patients with stage II and III essential hypertension.There is also an additive effect when combining the two agents that lowers BP more significantly than either monotherapy.
Antihypertensive treatment with moexipril plus HCTZ vs metoprolol plus HCTZ in patients with mild-to-moderate hypertension. [1997.02]
Combination therapy with the new ACE inhibitor moexipril plus hydrochlorothiazide (HCTZ) results in significant blood pressure (BP) reductions. This study compares the efficacy and safety of moexipril plus HCTZ to that of a standard combination treatment in patients with mild-to-moderate hypertension...
Clinical Trials Related to Uniretic (Moexipril / Hydrochlorothiazide)
A Study to Compare the Relative Bioavailability of Moexipril HCl/Hydrochlorothiazide in Healthy Adult Volunteers Under Fasting Conditions [Completed]
The purpose of this study was to evaluate the relative bioavailability of Paddock
Laboratories, Inc.'s test formulation of Moexipril/ Hydrochlorothiazide 15mg/25mg tablets
with a reference formulation Uniretic®(Moexipril/ Hydrochlorothiazide) 15mg/25mg tablets,
under fasting conditions.
Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions [Completed]
The objective of this study is to compare the relative bioavailability of Moexipril
HCl/hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA
Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy,
adult non-smoking subjects under fasting conditions.
Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions [Completed]
The objective of this study is to compare the relative bioavailability of moexipril HCl/
hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals
USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult,
non-smoking subjects under non-fasting conditions.